Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel Free GNCAQ Stock Alerts

Genocea Biosciences (GNCAQ) Competitors

Genocea Biosciences logo
Compare

GNCAQ vs. SCPS, TRVN, SYRS, NAVB, and GNCA

Should you buy Genocea Biosciences stock or one of its competitors? Genocea Biosciences's main competitors and comparable companies include Scopus BioPharma (SCPS), Trevena (TRVN), Syros Pharmaceuticals (SYRS), Navidea Biopharmaceuticals (NAVB), and Genocea Biosciences (GNCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Genocea Biosciences compare to Scopus BioPharma?

Genocea Biosciences (NASDAQ:GNCAQ) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Scopus BioPharma N/A N/A N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Scopus BioPharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Genocea Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.32, meaning that its share price is 132% less volatile than the broader market.

Summary

Genocea Biosciences beats Scopus BioPharma on 1 of the 1 factors compared between the two stocks.

How does Genocea Biosciences compare to Trevena?

Genocea Biosciences (NASDAQ:GNCAQ) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Genocea Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market. Comparatively, Trevena has a beta of -1.99, meaning that its share price is 299% less volatile than the broader market.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Trevena Neutral

13.6% of Trevena shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Genocea Biosciences has higher earnings, but lower revenue than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Trevena$443K0.14-$40.29M-$47.04N/A

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Trevena N/A N/A -119.55%

Summary

Genocea Biosciences and Trevena tied by winning 3 of the 6 factors compared between the two stocks.

How does Genocea Biosciences compare to Syros Pharmaceuticals?

Genocea Biosciences (NASDAQ:GNCAQ) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Genocea Biosciences has higher earnings, but lower revenue than Syros Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A

Genocea Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Syros Pharmaceuticals N/A -3,369.56%-97.04%

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Syros Pharmaceuticals Neutral

Genocea Biosciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

91.5% of Syros Pharmaceuticals shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Syros Pharmaceuticals beats Genocea Biosciences on 4 of the 7 factors compared between the two stocks.

How does Genocea Biosciences compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Genocea Biosciences Neutral

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Genocea Biosciences N/A N/A N/A

Genocea Biosciences has lower revenue, but higher earnings than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

Summary

Navidea Biopharmaceuticals beats Genocea Biosciences on 3 of the 5 factors compared between the two stocks.

How does Genocea Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

0.6% of Genocea Biosciences shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Genocea Biosciences Neutral

Genocea Biosciences has lower revenue, but higher earnings than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market.

Genocea Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Genocea Biosciences N/A N/A N/A

Summary

Genocea Biosciences beats Genocea Biosciences on 4 of the 6 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNCAQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNCAQ vs. The Competition

Export
MetricGenocea BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5K$12.13B$7.18B$13.18B
Dividend YieldN/A2.63%2.52%19.60%
P/E Ratio0.00631.84198.7718.91
Price / SalesN/A747.00565.6979.10
Price / CashN/A84.0876.6852.75
Price / BookN/A9.1510.515.92
Net IncomeN/A$2.82B$3.50B$380.90M

Genocea Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$5KN/AN/A70
SCPS
Scopus BioPharma
N/A$0.00
-33.3%		N/AN/A$17KN/AN/A13
TRVN
Trevena
N/A$0.01
flat		N/A+450.0%$12K$443KN/A23
SYRS
Syros Pharmaceuticals
N/A$0.00
flat		N/A-92.0%$11K$386KN/A68
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GNCAQ) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...
Weiss Ratings | Sponsoredtc pixel
Elon's next millionaires start October 24?
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...
Behind the Markets | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel